Compare Stocks

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GILD Gilead Sciences	$66.76 +0.9%	$72.10	$65.90 ▼ $87.86	$83.12B	0.19	7.35 million shs	10.66 million shs

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GILD Gilead Sciences	-1.15%	-3.63%	-9.88%	-24.21%	-21.34%

Tiny Biotech Stock Wins $75 Billion Patent (Ad)

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GILD Gilead Sciences	5 of 5 stars	4.1	3.0	4.2	4.1	3.8	2.5	3.8

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GILD Gilead Sciences	2.27	Hold	$84.71	26.89% Upside

Current Analyst Ratings

Latest GILD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/19/2024	GILD Gilead Sciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$105.00
4/17/2024	GILD Gilead Sciences	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$81.00 ➝ $75.00
3/4/2024	GILD Gilead Sciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$84.00 ➝ $77.00
2/22/2024	GILD Gilead Sciences	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$101.00 ➝ $90.00
2/22/2024	GILD Gilead Sciences	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$91.00 ➝ $82.00
2/14/2024	GILD Gilead Sciences	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$76.00 ➝ $75.00
2/12/2024	GILD Gilead Sciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$85.00 ➝ $80.00
2/12/2024	GILD Gilead Sciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$115.00 ➝ $105.00
2/7/2024	GILD Gilead Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$80.00 ➝ $78.00
2/7/2024	GILD Gilead Sciences	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$78.00 ➝ $76.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GILD Gilead Sciences	$27.12B	3.07	$8.93 per share	7.48	$18.26 per share	3.66

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GILD Gilead Sciences	$5.67B	$4.50	14.84	9.12	0.92	20.89%	38.85%	13.60%	4/25/2024 (Confirmed)

Latest GILD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
4/25/2024	N/A	GILD Gilead Sciences	$1.56	N/A	-$1.56	N/A	N/A	N/A
2/6/2024	Q4 23	GILD Gilead Sciences	$1.76	$1.72	-$0.04	$2.30	$7.10 billion	$7.12 billion

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GILD Gilead Sciences	$3.08	4.61%	+3.32%	68.44%	9 Years

Latest GILD Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/1/2024	GILD Gilead Sciences	Quarterly	$0.77	4.14%	3/14/2024	3/15/2024	3/28/2024

(Data available from 1/1/2013 forward)

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GILD Gilead Sciences	1.08	1.43	1.27

Ownership

Institutional Ownership

Company	Institutional Ownership
GILD Gilead Sciences	83.67%

Insider Ownership

Company	Insider Ownership
GILD Gilead Sciences	0.16%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
GILD Gilead Sciences	18,000	1.25 billion	1.24 billion	Optionable

GILD Headlines

Source	Headline
	Gilead Sciences (GILD) Increases Despite Market Slip: Here's What You Need to Know zacks.com - April 19 at 6:51 PM
	Gilead Sciences (NASDAQ:GILD) Stock Rating Reaffirmed by Oppenheimer marketbeat.com - April 19 at 11:28 AM
	Xponance Inc. Increases Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) marketbeat.com - April 19 at 10:17 AM
	Gilead Sciences (NASDAQ:GILD) Sets New 52-Week Low on Analyst Downgrade americanbankingnews.com - April 19 at 5:36 AM
	Gilead Sciences (NASDAQ:GILD) PT Lowered to $75.00 americanbankingnews.com - April 19 at 2:36 AM
	Gilead Sciences (GILD) Sees a More Significant Dip Than Broader Market: Some Facts to Know zacks.com - April 18 at 7:06 PM
	Gilead Sciences Publishes 2023 ESG Impact Report finance.yahoo.com - April 18 at 5:59 PM
	Hold Rating on Gilead Sciences Amidst Q1 Revenue Shortfall and Acquisition Concerns markets.businessinsider.com - April 18 at 12:59 PM
	Federated Hermes Inc. Grows Position in Gilead Sciences, Inc. (NASDAQ:GILD) marketbeat.com - April 18 at 12:21 PM
	Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for zacks.com - April 18 at 11:08 AM
	UBS Group Lowers Gilead Sciences (NASDAQ:GILD) Price Target to $75.00 marketbeat.com - April 18 at 8:23 AM
	Gilead Sciences (GILD) to Release Earnings on Thursday americanbankingnews.com - April 18 at 2:32 AM
	Goodman Advisory Group LLC Sells 17,821 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) marketbeat.com - April 17 at 12:48 PM
	Gilead Sciences (NASDAQ:GILD) Sets New 1-Year Low at $67.15 marketbeat.com - April 17 at 10:51 AM
	GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO INNOVATIVE INITIATIVES IN ASIA finance.yahoo.com - April 17 at 7:58 AM
	HealthInvest Partners AB Makes New Investment in Gilead Sciences, Inc. (NASDAQ:GILD) marketbeat.com - April 16 at 6:41 PM
	Gilead Sciences with World Hepatitis Alliance to award US$ 4 mn ALL4LIVER grant for viral hepatitis elimination by 2030 pharmabiz.com - April 16 at 10:54 AM
	Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know zacks.com - April 16 at 10:01 AM
	Bourgeon Capital Management LLC Sells 71,313 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) marketbeat.com - April 15 at 3:00 PM
	Should You Buy the 3 Highest-Paying Dividend Stocks in the Nasdaq? fool.com - April 15 at 8:00 AM
	GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY LED INITIATIVES IN HONG KONG finance.yahoo.com - April 15 at 2:50 AM
	GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY-LED INITIATIVES IN ASIA finance.yahoo.com - April 15 at 2:50 AM
	Gilead Sciences, Inc. (NASDAQ:GILD) Short Interest Up 17.2% in March marketbeat.com - April 14 at 7:21 PM
	Gilead Sciences, Inc. (NASDAQ:GILD) Stake Lessened by Conning Inc. marketbeat.com - April 14 at 3:54 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Value Stocks Too Small For Buffett’s Portfolio
March 28, 2024 12:16 PM
View 3 Value Stocks Too Small For Buffett’s Portfolio
Foot Locker Builds Up Another Head of Steam; Gains Imminent
March 28, 2024 10:58 AM
View Foot Locker Builds Up Another Head of Steam; Gains Imminent
5 Stocks in the Current Bull Market with Upside to Come
April 5, 2024 10:14 AM
View 5 Stocks in the Current Bull Market with Upside to Come
Consumer Sentiment Highest Since 2021, 3 Stocks Leading the Way
April 1, 2024 9:25 AM
View Consumer Sentiment Highest Since 2021, 3 Stocks Leading the Way
Biotech Sector Nears Breakout: Will it Outperform in Q2?
April 3, 2024 6:10 AM
View Biotech Sector Nears Breakout: Will it Outperform in Q2?

All Headlines

Company Descriptions

Gilead Sciences

NASDAQ:GILD

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial